Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 60% Improvement Relative Risk Ventilation 76% Hospitalization time 34% c19early.org/mf Usman et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 75 patients in the USA Lower mortality (p=0.21) and ventilation (p=0.054), not stat. sig. Usman et al., J. Thrombosis and Thrombolysis, doi:10.1007/s11239-022-02631-7 Favors metformin Favors control
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
Usman et al., Journal of Thrombosis and Thrombolysis, doi:10.1007/s11239-022-02631-7
Usman et al., Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic.., Journal of Thrombosis and Thrombolysis, doi:10.1007/s11239-022-02631-7
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 75 diabetes patients, 34 on metformin, showing improved clinical outcomes with treatment, without statistical significance.
risk of death, 59.8% lower, RR 0.40, p = 0.21, treatment 3 of 34 (8.8%), control 9 of 41 (22.0%), NNT 7.6.
risk of mechanical ventilation, 75.9% lower, RR 0.24, p = 0.05, treatment 2 of 34 (5.9%), control 10 of 41 (24.4%), NNT 5.4.
hospitalization time, 33.7% lower, relative time 0.66, p = 0.13, treatment 34, control 41.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Usman et al., 18 Jan 2022, retrospective, USA, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Journal of Thrombosis and Thrombolysis https://doi.org/10.1007/s11239-022-02631-7 Metformin use in patients hospitalized with COVID‑19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes Abira Usman1 · Kevin P. Bliden1 · Alastair Cho1 · Naval Walia1 · Christophe Jerjian1 · Arvind Singh1 · Parshotam Kundan1 · Sanchit Duhan1 · Udaya S. Tantry1 · Paul A. Gurbel1 Accepted: 30 December 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 Abstract Diabetes mellitus (DM) is associated with a greater risk of COVID-19 and an increased mortality when the disease is contracted. Metformin use in patients with DM is associated with less COVID-19-related mortality, but the underlying mechanism behind this association remains unclear. Our aim was to explore the effects of metformin on markers of inflammation, oxidative stress, and hypercoagulability, and on clinical outcomes. Patients with DM on metformin (n = 34) and metformin naïve (n = 41), and patients without DM (n = 73) were enrolled within 48 h of hospital admission for COVID-19. Patients on metformin compared to naïve patients had a lower white blood cell count (p = 0.02), d-dimer (p = 0.04), urinary 11-dehydro thromboxane ­B2 (p = 0.01) and urinary liver-type fatty acid binding protein (p = 0.03) levels and had lower sequential organ failure assessment score (p = 0.002), and intubation rate (p = 0.03), fewer hospitalized days (p = 0.13), lower in-hospital mortality (p = 0.12) and lower mortality plus nonfatal thrombotic event occurrences (p = 0.10). Patients on metformin had similar clinical outcomes compared to patients without DM. In a multiple regression analysis, metformin use was associated with less days in hospital and lower intubation rate. In conclusion, metformin treatment in COVID-19 patients with DM was associated with lower markers of inflammation, renal ischemia, and thrombosis, and fewer hospitalized days and intubation requirement. Further focused studies are required to support these findings. Keywords COVID-19 · Diabetes · Metformin · Thromboelastography · Biomarker · Death · Intubation Highlights • Fasting blood glucose level in patients with COVID-19 has been shown to be associated with severity of the disease and poor outcomes, including mortality. • Metformin use in patients with DM is associated with less COVID-19-related mortality, but the underlying mechanism behind this association remains unclear. • In this single center study, metformin treatment in COVID-19 patients with DM was associated with lower * Paul A. Gurbel pgurbel@lifebridgehealth.org 1 Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Lifebridge Health, Baltimore, MD 21215, USA markers of inflammation, renal ischemia, and thrombosis, and fewer hospitalized days and intubation requirement. • In a multiple regression analysis, metformin use was associated with less days in hospital and lower intubation rate.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit